Slide 1: First Quarter 2010 Webcast
Exhibit 99.1 First Quarter 2010 Webcast April 27, 2010
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation, made on April 27, 2010, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and a
Slide 3: Business Overview
Business Overview Kevin Buehler President and Chief Executive Officer
Slide 4: Performance Results
Performance Results Strong top-line sales growth – Q1 2010 organic growth of 9.6% (+15.3% reported) Leveraging P&L to drive earnings growth – Q1 2010 adjusted EPS growth of 23.2% to $1.91 (+25.2% reported to $1.89) Commercial execution driving operational results – Reinforcing and building leading m
Slide 5: Multiple Sources of Product Growth
Multiple Sources of Product Growth Q1 Global Sales by Product Line $1,000 +16.3% Reported +14.7% Reported +13.9% Reported +11.7% Organic Growth +8.3% Organic Growth +7.7% Organic Growth $800 $772 $728 $600 $673 $626 (dollars in millions) $400 $200 $221 $194 $0 Pharmaceuticals Surgical Consumer Q1 20
Slide 6: Balanced Global Growth
Balanced Global Growth Q1 2010 Sales by Geography $326 Reported: +24.0% $726 Organic Growth: +12.2% Emerging Markets Reported: +10.3% Organic Growth: +10.0% 18.9% U.S. 42.2% Developed International 38.9% $669 Reported: +17.0% Organic Growth: +8.0% (dollars in millions) Growth rates as compared to sa
Slide 7: Gaining Market Share in Key Categories
Gaining Market Share in Key Categories Global U.S. RX Growth February YTD February YTD Brand Market Brand Market TRAVATAN® Family 11.1% 5.3% 10.8% 1.2% Azopt® + AZARGA® 15.2% 4.6% 7.2% 7.9% Vigamox® * 7.2% 2.8% -2.0% -4.0% NEVANAC® 55.3% 30.4% 11.8% -2.0% Patanol® + PatadayTM -20.3% -25.3% -5.7% -6.
Slide 8: Commercial Execution Driving Market Performance
Commercial Execution Driving Market Performance U.S. Total IOL Market Share U.S. PC-IOL Market Share 70 70 59.6% 58.3% 60 60 57.5% 50 50 45.0% (shares by percentage) (shares by percentage) 40 40 30 30 20 20 10 10 0 0 Q4 2008 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q4 2008 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Alc
Slide 9: Key R&D Pipeline Activities
Key R&D Pipeline Activities Early-Stage Late-Stage Global Registration CATARACT CATARACT CATARACT AcrySof® new design AcrySof® ReSTOR® Toric AcrySof® ReSTOR® +3.0 (Japan) AcrySof® IQ Toric diopter expansions DisCoVisc® (Japan) GLAUCOMA REFRACTIVE REFRACTIVE Glaucoma NMEs FS-200 femtosecond laser Gla
Slide 10: Positioned for Balanced and Sustainable Growth
Positioned for Balanced and Sustainable Growth Strategically focused on important medical specialty – Eye care as a faster-growing health care specialty sector Long-term growth opportunity – Attractive market fundamentals, aging global demographics – Significant unmet medical needs – Emerging market
Slide 11: Financial Review
Financial Review Rick Croarkin Senior Vice President, Finance and Chief Financial Officer
Slide 12: Sales
Sales Sales (dollars in millions) +15.3% Reported +9.6% Organic Growth $1,800 $1,721 $1,600 $1,493 $1,400 $1,200 Q1 2009 Q1 2010 Growth rates as compared to same period in prior year Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between year
Slide 13: Operating Income
Operating Income Reported Adjusted (dollars in millions) (dollars in millions) $800 $800 +27.0% +19.0% $700 $700 $653 $600 $600 $633* $500 $500 $532* $514 $400 $400 Q1 2009 Q1 2010 Q1 2009 Q1 2010 % of % of 34.4% 37.9% 35.6% 36.8% Sales Sales Growth rates as compared to same period in prior year * A
Slide 14: Net Earnings and Diluted EPS
Net Earnings and Diluted EPS Net Earnings Diluted EPS (dollars in millions) $700 $2.20 +26.8% Reported +25.2% Reported $600 $581 * $1.90 $1.91 * $573 $1.89 $500 $465 * $452 $1.60 $400 $1.55 * $1.51 $300 $1.30 Q1 2009 Q1 2010 Q1 2009 Q1 2010 Reported 30.3% 33.3% % of Sales Growth rates as compared to
Slide 15: 2010 Full Year Financial Guidance
2010 Full Year Financial Guidance • Organic growth in the mid-to-high single digits • Diluted earnings per share: Adjusted EPS guidance $7.30 - $7.55 • Includes on-going U.S. health care reform costs – $20 million full-year sales impact – $0.06 full-year diluted EPS impact • Project and deal timing
Slide 16: First Quarter 2010 Webcast
First Quarter 2010 Webcast April 27, 2010
Slide 17: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (in millions) Three Months Ended Foreign March 31, Currency Acquisition Organic 2010 2009 Change Change Change Change Sales by Product Line: Pharmaceutical $ 728 $ 626 16.3% 4.6% --% 11.7% Surgical 77
Slide 18: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures Foreign Reported Currency Acquisition Organic Sales Change Change Change Change Glaucoma pharmaceuticals 30.0 % 6.0 % -- % 24.0 % Infection/inflammation 13.9 4.0 -- 9.9 ® Vigamox 19.4 1.4 -- 18.0 Intr
Slide 19: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (in millions) Operating Income Q1 2010 Q1 2009 Growth % As Reported $ 653 $ 514 27.0% 2010 Change in Royalty Estimate (24) -- -- 2010 Change-in- Control Expenses 4 -- -- 2009 Reduction in Force -- 18
Slide 20: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures Diluted EPS Q1 2010 Q1 2009 Growth % As Reported $ 1.89 $ 1.51 25.2% 2010 Change in Royalty Estimate (0.07) -- -- 2010 Change-in- Control Expenses 0.01 -- -- 2010 U.S. Health Care Reform * 0.08 -- --